columbianetin: RN given for cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
columbianetin : The angular furanocoumarin analogue of the linear furanocoumarin marmesin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 150888 |
| CHEMBL ID | 155115 |
| CHEBI ID | 59948 |
| SCHEMBL ID | 50251 |
| MeSH ID | M0135285 |
| Synonym |
|---|
| columbianetin |
| 52842-47-4 |
| (+-)-columbianetin |
| CHEBI:59948 , |
| 1147-29-1 |
| 8-(2-hydroxypropan-2-yl)-8,9-dihydro-2h-furo[2,3-h]chromen-2-one |
| 8,9-dihydro-8-(1-hydroxy-1-methylethyl)-2h-furo[2,3-h]1-benzopyran-2-one |
| 8-(2-hydroxypropan-2-yl)-8,9-dihydrofuro[2,3-h]chromen-2-one |
| FT-0665159 |
| 2h-furo(2,3-h)-1-benzopyran-2-one, 8,9-dihydro-8-(1-hydroxy-1-methylethyl)- |
| 8-(1-hydroxy-1-methyl-ethyl)-8,9-dihydro-furo[2,3-h]chromen-2-one |
| 8-(1-hydroxy-1-methyl-ethyl)-8,9-dihydrofuro[2,3-h]chromen-2-one |
| HMS3352J21 |
| SCHEMBL50251 |
| dihydrooroselol |
| AKOS027324052 |
| 8-(2-hydroxypropan-2-yl)-8,9-dihydro-2h-furo[2,3-h][1]benzopyran-2-one |
| DTXSID60921469 |
| HY-N5003 |
| CS-0032059 |
| Q27126979 |
| CHEMBL155115 |
Columbianetin (CBT) is a major active compound of radix angelicae pubescentis. It is used in the treatment of OA.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Columbianetin (CBT) is a major active compound of radix angelicae pubescentis, which is used in the treatment of OA." | ( Columbianetin alleviates lipopolysaccharides (LPS)-induced inflammation and apoptosis in chondrocyte through activation of autophagy by inhibiting serum and glucocorticoid-induced protein kinase 1 (SGK1) expression. An, G; Chen, W; Fu, Z; Ji, X; Tan, M; Wei, C; Xu, Y; Zhang, X; Zheng, H; Zhou, M, 2022) | 2.89 |
The pharmacokinetic properties of columbianetin in rat after oral administration were characterized as rapid oral absorption, quick clearance and good absolute bioavailability.
| Excerpt | Reference | Relevance |
|---|---|---|
| " This method was suitable for the determination and pharmacokinetic study of columbianetin in rat plasma after both intravenous and oral administration." | ( The pharmacokinetics and oral bioavailability studies of columbianetin in rats after oral and intravenous administration. Bai, Y; Chang, YX; Gao, XM; Li, J; Luo, Q; Ma, L; Ma, WF; Wang, CP; Zhang, BL, 2013) | 0.86 |
| "The pharmacokinetic properties of columbianetin in rat after oral administration were characterized as rapid oral absorption, quick clearance and good absolute bioavailability." | ( The pharmacokinetics and oral bioavailability studies of columbianetin in rats after oral and intravenous administration. Bai, Y; Chang, YX; Gao, XM; Li, J; Luo, Q; Ma, L; Ma, WF; Wang, CP; Zhang, BL, 2013) | 0.91 |
Columbianetin is one of the main active constituents isolated from RAP, which has been shown to have various biological activities. The absorption characteristics and oral bioavailability dose proportionality of columbianETin in vivo were not studied.
| Class | Description |
|---|---|
| tertiary alcohol | A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. |
| furanocoumarin | Any furochromene that consists of a furan ring fused with a coumarin. The fusion may occur in different ways in give several isomers. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1498663 | Cytoprotective activity against 100 uM t-BHP-induced oxidative stress in human HepG2 cells assessed as cell viability preincubated for 1 hr followed by t-BHP addition measured after 3 hrs by CCK-8 assay (Rvb = 22%) | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis of coumarin derivatives and their cytoprotective effects on t-BHP-induced oxidative damage in HepG2 cells. |
| AID1498662 | Cytotoxicity against human HepG2 cells at 10 uM | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14 | Synthesis of coumarin derivatives and their cytoprotective effects on t-BHP-induced oxidative damage in HepG2 cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.59) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||